Abbott’s Panbio Rapid Antigen Test Receives CE Mark for Mass COVID-19 Screening
Tuba Khan
Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com
Related post
Abbott’s Panbio Rapid Antigen Test Receives CE...
January 27, 2021AbbVie’s Rinvoq (upadacitinib) Receives the EC’s Approval...
January 27, 2021Regeneron Reports Results of REGEN-COV Antibody Cocktail...
January 27, 2021Shionogi Concludes a License Agreement with BioAge...
January 27, 2021Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US